drugset
drugset / Trial / NCT04293094

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

NCT04293094 ↗

Phase 1 Completed 66 enrolled Volastra Therapeutics, Inc. Amgen · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Timeline

Start
2020-03-11
Primary completion
2022-10-24
Completion
2023-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 650 Small molecule — Oral

Indications

neoplasm